National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Enzalutamide (Xtandi®) for nmCRPC. HTA ID: 18056

Enzalutamide (Xtandi®) is indicated for the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).


NCPE Assessment Process Complete
Rapid review commissioned 18/12/2018
Rapid review completed 06/02/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of enzalutamide in combination with ADT compared with the current standard of care
Full pharmacoeconomic assessment commissioned by HSE 13/02/2019
Pre-submission consultation with Applicant 11/06/2019
Full HTA submission received from Applicant 30/04/2021
Preliminary review sent to Applicant 14/12/2021
NCPE assessment re-commenced 25/01/2022
Factual accuracy check sent to Applicant 08/04/2022
NCPE assessment re-commenced 21/04/2022
NCPE assessment completed 24/05/2022
NCPE assessement outcome Following assessment of the company submission, the NCPE recommend that enzalutamide (Xtandi®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 201